

Summary of Financial Report for the 2nd Quarter of FY ending December 2009

August 13, 2009

Company Name: Carna Biosciences, Inc.

Listed Securities Exchange: JQ • NEO

Stock Code: 4572 JQ • NEO

URL <http://www.carnabio.com>

Representative: Kohichiro Yoshino, President

Contact: Norio, Aikawa, Director

TEL (078)302-7039

(Rounding down to the nearest million yen)

1. Consolidated results for the 2nd Quarter of FY2009 (January 1, 2009 to June 30, 2009)

(1)Business Results(Consolidated) (% indicates the increase / decrease from previous first quarter)

	Total Revenue		Operating income		Ordinary income		Net income	
	million yen	%	million yen	%	million yen	%	million yen	%
2 nd quarter of FY2009	318	-	-162	-	-158	-	-162	-
2 nd quarter of FY2008	238	-	-118	-	-167	-	-168	-

	Net income per share	Net income per share (diluted)
	yen	yen
2 nd quarter of FY2009	-3,049.26	-
2 nd quarter of FY2008	-3,417.21	-

Note: Net income per share of 2nd quarter of FY2008 and 2009(Diluted): No statement - We had net loss per share even though we had diluted shares.

(2)Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio	Net assets per share
	million yen	million yen	%	Yen
2 nd quarter of FY2009	1,781	1,658	93.1	31,141.72
FY2008 as reference	2,070	1,789	86.4	33,587.30

2. Cash Dividends

(criterion)	Dividends per share				
	End of 1 st quarter period	End of 2 nd quarter period	End of 3 rd quarter period	End of FY	FY
	yen	yen	yen	yen	yen
FY2008	-	0.00	-	0.00	0.00
FY2009	-	0.00			
FY2009(forecast)			-	0.00	0.00

3. Consolidated forecast for FY2009 (January 1, 2009 to December 31, 2009)

(% indicates the increase/decrease from FY2008)

	Total revenue		Operating income		Ordinary income		Net income		Net income per share
	million yen	%	million yen	%	million yen	%	million yen	%	Yen
FY2009	710	42.1	-359	-	-372	-	-363	-	-6,814.34

*Disclaimer regarding appropriate use of forecasts and related points of note

1. The above-mentioned forecasts are revised on August 13.
2. The revised forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of the release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.
3. The forecasted net income per share above is calculated based on 53,270 issued shares.